Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $165.00 short call and a strike $170.00 long call offers a potential 16.28% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $165.00 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock rose above the $170.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 47.73 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Your first trade for Friday
Thu, 12 Jun 2014 22:12:37 GMT
Fast Money Final Trade: BP, TWTR, AGN, VRX, CNQ
Thu, 12 Jun 2014 21:58:00 GMT
Why Allergan's Shareholders Should Be Wary About Valeant's (and Ackman's) Takeover Bid
Thu, 12 Jun 2014 19:10:00 GMT
Forbes – This article is by Mark Rogers, the founder and chief executive of BoardProspects.com. The battle between activist investor Bill Ackman and Allergan's chief executive and board over Valeant Pharmaceuticals' bid to take over Allergan, the maker of Botox, has been generating a lot of news lately. But it’s what doesn’t get much press—what […]
Valeant Pharma's Arguments About Drug Research Are Misleading And Wrong
Thu, 12 Jun 2014 15:52:00 GMT
Goldman’s Unusually Quiet Role in Battle for Botox Maker
Thu, 12 Jun 2014 15:34:55 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook